

NEW ZEALAND DATA SHEET

1 PRODUCT NAME

Cefalexin Lupin 250 mg and 500 mg capsules

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains cefalexin monohydrate equivalent to 250 mg cefalexin or 500 mg cefalexin.

For the full list of excipients, see **Section 6.1 List of Excipients**.

3 PHARMACEUTICAL FORM

Cefalexin Lupin 250 mg capsules are size '2' capsules with a dark green cap, imprinted with "250" in black ink, and a white body.

Cefalexin Lupin 500 mg capsules are size '0' capsules with a dark green cap, imprinted with "500" in black ink, and a light green body.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Cefalexin Lupin capsules are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:

- Bacterial sinusitis caused by streptococci, *S. pneumoniae*, and *Staphylococcus aureus* (methicillin-sensitive only).

Respiratory tract infections caused by *S. pneumoniae* and *S. pyogenes*. (Penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present.)

- Otitis media due to *S. pneumoniae*, *H. influenzae*, staphylococci, streptococci and *M. catarrhalis*.
- Skin and soft tissue infections caused by staphylococci and/or streptococci.
- Genitourinary tract infections, including acute prostatitis, caused by *E. coli*, *P. mirabilis* and *Klebsiella pneumoniae*.

The effectiveness of cefalexin capsules in the treatment of bacterial infections of the brain and spinal column has not been established and Cefalexin Lupin is not indicated in these conditions.

Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.

4.2 Dose and Method of Administration

Dosage

Adults

The adult dosage ranges from 1 g to 4 g daily in divided doses. The usual adult dose is 250 mg every 6 hours. For the following infections, a dosage of 500 mg may be administered every 12 hours: streptococcal pharyngitis or tonsillitis; mild, uncomplicated urinary tract infections; and skin and soft tissue infections. For more severe infections or those caused by less susceptible organisms, larger doses may be needed. If daily doses of cefalexin greater than 4 g are required, parenteral cephalosporins, in appropriate doses, should be considered.

Twice daily dosing is not recommended when doses larger than 1 g daily are administered.

Children

The usual recommended daily dosage for children is 25 mg/kg to 50 mg/kg in divided doses. For streptococcal pharyngitis in patients over 1 year of age, tonsillitis, mild, uncomplicated urinary tract infections, and for skin and soft- tissue infections, the total daily dose may be divided and administered every 12 hours.

In severe infections, the dosage may be doubled.

In the therapy of otitis media, clinical studies have shown that a dosage of 75 mg/kg/day to 100 mg/kg/day in 4 divided doses is required.

In the treatment of β -haemolytic streptococcal infections, a therapeutic dosage of cefalexin should be administered for at least 10 days.

Impaired renal function: see **Section 4.4 Special Warnings and Precautions For Use**.

Method of Administration

Cefalexin Lupin capsules are administered orally.

4.3 Contraindications

Cefalexin Lupin capsules are contraindicated in patients who have had previous experience of a major allergy to a cephalosporin or penicillin, or those who have experienced hypersensitivity to any of the excipients (see **Section 4.4 Special Warnings and Precautions For Use**).

4.4 Special Warnings and Precautions for Use

Warnings

Before cefalexin therapy is instituted, careful inquiry should be made concerning previous hypersensitivity reactions to cephalosporins and penicillin. Cefalexin should be given with caution to patients who have experienced symptoms of allergy associated with a cephalosporin or penicillin.

There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and the cephalosporins. Patients have been reported to have had severe reactions (including anaphylaxis) to both medicines.

If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the usual agents (eg. adrenaline or other pressor amines, antihistamines or corticosteroids).

Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics (including macrolides, semisynthetic penicillins and cephalosporins). A toxin produced with *Clostridium difficile* appears to be the primary cause. The severity of the colitis may range from mild to life threatening. It is important to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics including cephalosporin. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to medicine discontinuance alone.

However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against *Clostridium difficile* should be considered. Fluids, electrolytes and protein replacement should be provided when indicated.

Drugs which delay peristalsis, eg. opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the condition and should not be used.

Broad-spectrum antibiotics should therefore be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Patients should be followed carefully so that any side effects or unusual manifestations of drug idiosyncrasy may be detected.

Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Neurotoxicity

There have been reports of neurotoxicity associated with cephalosporin treatment, including encephalopathy, seizures and/or myoclonus. Neurotoxicity is more likely observed in elderly patients and patients with renal impairment, central nervous system disorders and those receiving intravenous cephalosporins. Withdrawal of the medicine should be considered if there are signs of neurotoxicity. Anticonvulsant therapy can be given if clinically indicated.

Use in Renal Impairment

Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

Use in the Elderly

No data available.

Paediatric Use

No data available.

Severe Cutaneous Adverse Reactions

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients taking beta-lactam antibiotics. When SCAR is suspected, cefalexin should be discontinued immediately and an alternative treatment should be considered.

Effects on Laboratory Tests

The quantitative determination of urinary protein excretion using strong acids is misleading during cefalexin therapy as precipitation of cefalexin in the urine may occur.

A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution or with Clinitest®.

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.

4.5 Interactions with Other Medicines and Other Forms of Interactions

As with other beta-lactams, the renal excretion of cefalexin is inhibited by probenecid.

In healthy subjects given single 500 mg doses of cefalexin and metformin, plasma metformin C_{max} and AUC increased by an average of 34% and 24%, respectively, and metformin renal clearance decreased by an average of 14%. No information is available about the interaction of cefalexin and metformin following multiple dose administration.

Administration of a cephalosporin to a metformin-treated patient may result in increased metformin exposure.

4.6 Fertility, Pregnancy and Lactation

Effects on Fertility

No data available.

Use in Pregnancy

Category A

Use in Lactation

Cefalexin is excreted in the milk. Caution should be exercised when cefalexin is administered to a nursing woman. Alternative feeding arrangements for the infant should be considered.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Adverse drug reactions reported with cefalexin are very rare (<0.01%) and are listed below:

- **Blood and Lymphatic System Disorders:** Eosinophilia; neutropenia; thrombocytopenia; haemolytic anaemia.
- **Gastrointestinal Disorders:** Nausea; vomiting; diarrhoea; dyspepsia; abdominal pain.
- **General Disorders and Administration Site Conditions:** Fatigue.
- **Hepatobiliary Disorders:** Cholestatic jaundice; transient hepatitis; elevated Serum Glutamic-Oxaloacetic Transaminase (SGOT); elevated Serum Glutamic-Pyruvic Transaminase (SGPT).
- **Immune System Disorders:** Allergic reactions; urticaria; angioedema. These reactions usually subsided upon discontinuation of the drug. Anaphylaxis has also been reported.
- **Infections and Infestations:** Pseudomembranous colitis.
- **Musculoskeletal and Connective Tissue Disorders:** Joint disorder; arthralgia; arthritis.
- **Nervous System Disorders:** Dizziness; headache; seizure. Encephalopathy; myoclonus (frequency not known).
- **Psychiatric Disorders:** Hallucinations; agitation; confusion.
- **Renal and Urinary Disorders:** Reversible interstitial nephritis.
- **Reproductive and Breast Disorders:** Genital and anal pruritus; genital moniliasis; vaginitis; vaginal discharge.
- **Skin and Subcutaneous Tissue Disorders:** Rash; erythema multiforme.

These reactions usually subsided upon discontinuation of the drug.

SCAR, including SJS, TEN, DRESS and AGEP, and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) (baboon syndrome) have been reported in beta-lactam antibiotics.

Reporting of Suspected Adverse Effects

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://pophealth.my.site.com/carmreportnz/s/>

4.9 Overdose

Signs and Symptoms

Symptoms of oral overdose may include nausea, vomiting, epigastric distress, diarrhoea and haematuria. If other symptoms are present, it is probably secondary to an underlying disease state, an allergic reaction, or toxicity due to ingestion of a second medication.

Treatment

In the event of severe overdosage, general supportive care is recommended including close clinical and laboratory monitoring of haematological, renal, hepatic functions and coagulation status until the patient is stable.

Forced diuresis, peritoneal dialysis, haemodialysis, or charcoal haemoperfusion have not been established as beneficial for an overdose of cefalexin.

For information on the management of overdose, contact the Poisons Information Centre on 0800 POISON (0800 764 766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: antibacterials, first generation cephalosporins ATC code: J01DB01.

Cefalexin is a 7-(D- α -amino- α -phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate. Cefalexin has the molecular formula $C_{16}H_{17}N_3O_4S \cdot H_2O$ and the molecular weight is 365.4.

The nucleus of cefalexin is related to that of other cephalosporin antibiotics. The compound is a zwitterion; ie. the molecule contains both a basic and an acidic group. The isoelectric point of cefalexin in water is approximately 4.5 to 5. The crystalline form of cefalexin which is available is a monohydrate. It is a white crystalline solid having a bitter taste. Solubility in water is low at room temperature; 1 mg/mL or 2 mg/mL may be dissolved readily, but higher concentrations are obtained with increasing difficulty.

The cephalosporins differ from penicillins in the structure of the bicyclic ring system. Cefalexin has a D-phenylglycyl group as substituent at the 7-amino position and an unsubstituted methyl group at the 3-position.

Mechanism of Action

Cefalexin is a semi-synthetic cephalosporin antibiotic intended for oral administration.

Microbiology - *In vitro* Tests

In vitro tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cefalexin has been shown to be active against most strains of the following microorganisms both *in vitro* and in clinical infections as described in **Section 4.1 Therapeutic Indications**.

Aerobes, Gram-positive

Staphylococcus aureus (including penicillinase-producing strains); *Staphylococcus epidermidis* (penicillin-susceptible strains); *Streptococcus pneumoniae*; *Streptococcus pyogenes*.

Aerobes, Gram-negative

Escherichia coli; *Haemophilus influenza*; *Klebsiella pneumoniae*; *Moraxella catarrhalis*; *Proteus mirabilis*.

Note: Methicillin-resistant staphylococci and most strains of enterococci (*Enterococcus faecalis*) are resistant to cephalosporins including cefalexin. Penicillin-resistant *Streptococcus pneumoniae* is usually cross-resistant to beta-lactam antibiotics. It is not active against most strains of *Enterobacter* spp., *Morganella morganii* and *Proteus vulgaris*. It has no activity against *Pseudomonas* spp. or *Acinetobacter calcoaceticus*.

Susceptibility Tests - Diffusion Techniques

Quantitative methods that require measurement of zone diameters provide reproducible estimates of susceptibility of bacteria to antimicrobial compounds. One such standardised procedure¹ that has been recommended for use with discs to test the susceptibility of microorganisms to cephalexin uses the 30 microgram cefalotin disc. Interpretation involves correlation of the diameter obtained in the disc test with the minimum inhibitory concentration (MIC) for cephalexin.

Reports from the laboratory providing results of the standard single-disc susceptibility test with a 30 microgram cefalotin disc should be interpreted according to the following criteria:

Zone Diameter (mm)	Interpretation
Greater than or equal to 18	(S) Susceptible
15-17	(I) Intermediate
Less than or equal to 14	(R) Resistant

A report of "Susceptible" indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible medicine, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of medicine can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.

Measurement of MIC or minimum bactericidal concentration (MBC) and achieved antimicrobial compound concentrations may be appropriate to guide therapy in some infections (see **Section 5.2 Pharmacokinetic Properties** for information on drug concentrations achieved in infected body sites and other pharmacokinetic properties of this antimicrobial medicine.)

Standardised susceptibility test procedures require the use of laboratory control microorganisms. The 30 microgram cefalotin disc should provide the following zone diameters in these laboratory test quality control strains:

Micro-organism	Zone Diameter (mm)
<i>E. coli</i> ATCC 25922	15-21
<i>S. aureus</i> ATCC 25923	29-37

¹ National Committee for Clinical Laboratory Standards. *Performance Standards for Antimicrobial Disc Susceptibility Tests*—5th ed. Approved Standard NCCLS Document M2-A5, Vol 13, No 24, NCCLS, Villanova, PA, 1993.

Dilution Techniques

Quantitative methods that are used to determine MICs provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardised procedure uses a standardised dilution method² (broth, agar, microdilution) or equivalent with cephalothin powder. The MIC values obtained should be interpreted according to the following criteria:

MIC (mcg/mL)	Interpretation
Greater than or equal to 8	(S) Susceptible
16	(I) Intermediate
Less than or equal to 32	(R) Resistant

Interpretation should be as stated above for results using diffusion techniques.

As with standard diffusion techniques, dilution methods require the use of laboratory control microorganisms. Standard cephalothin powder should provide the following MIC values:

Microorganism	MIC (mcg/mL)
<i>E. coli</i> ATCC 25922	4-16
<i>E. faecalis</i> ATCC 29212	8-32
<i>S. aureus</i> ATCC 29213	0.12-0.5

5.2 Pharmacokinetic Properties

Absorption

Cefalexin is acid stable and may be given without regard to meals. It is rapidly absorbed after oral administration. Following doses of 250 mg, 500 mg and 1 g, average peak serum levels of approximately 9 mg/L, 18 mg/L and 32 mg/L respectively were obtained at one hour. Measurable levels were present six hours after administration.

Elimination

Cefalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the medicine was excreted unchanged in the urine within 8 hours. During this period, peak urine concentrations following the 250 mg, 500 mg and 1 g doses were approximately 1000 mg/L, 2200 mg/L and 5000 mg/L respectively.

5.3 Preclinical Safety Data

No further data of relevance.

6 PHARMACEUTICAL PARTICULARS

² National Committee for Clinical Laboratory Standards. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*--3rd ed. Approved Standard NCCLS Document M7-A3, Vol 13, No 25, NCCLS, Villanova, PA, 1993.

6.1 List of Excipients

- Microcrystalline cellulose.
- Magnesium stearate.

6.2 Incompatibilities

Not applicable

6.3 Shelf Life

24 months.

6.4 Special Precautions for Storage

Store below 30°C.

6.5 Nature and Contents of Container

Blister packs of 20 capsules.

6.6 Special Precautions for Disposal

No special requirements for disposal.

Any unused medicine or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE

Prescription medicine.

8 SPONSOR

Lupin NZ Limited
c/- BDO, Level 4, Building A, BDO Centre
4 Graham Street, Auckland, 1010
New Zealand

Phone: +64 9 8896972

9 DATE OF FIRST APPROVAL

24 April 2008

10 DATE OF REVISION OF THE TEXT

7 October 2024

SUMMARY TABLE OF CHANGES

Section Changed	Summary of New Information
1	Change in trade name from 'Cephalexin ABN' to 'Cefalexin Lupin'
8	Change of sponsor